Arcus Biosciences, Inc. (RCUS) is trading 11.50 percent lower at $22.25, down $2.89 on Friday, after announcing the discontinuation of its Phase 3 STAR-221 study conducted with Gilead Sciences.
The stock opened at $21.15 and has traded between $20.35 and $24.00 so far on the New York Stock Exchange. The bid sits at $22.54 and the ask at $22.60, with volume at 4,426,823 versus an average of 1,561,846.
Arcus shares are now trading well off their recent peak, within a 52-week range of $6.50 to $26.40.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.